148 related articles for article (PubMed ID: 23838926)
1. Visualising and quantifying angiogenesis in metastatic colorectal cancer : A comparison of methods and their predictive value for chemotherapy response.
Hansen TF; Nielsen BS; Jakobsen A; Sørensen FB
Cell Oncol (Dordr); 2013 Jul; 36(4):341-50. PubMed ID: 23838926
[TBL] [Abstract][Full Text] [Related]
2. The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer.
Hansen TF; Sørensen FB; Lindebjerg J; Jakobsen A
BMC Cancer; 2012 Mar; 12():83. PubMed ID: 22397399
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial.
Hansen TF; Christensen Rd; Andersen RF; Sørensen FB; Johnsson A; Jakobsen A
Br J Cancer; 2013 Sep; 109(5):1243-51. PubMed ID: 23922111
[TBL] [Abstract][Full Text] [Related]
4. Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer.
Hansen TF; Carlsen AL; Heegaard NH; Sørensen FB; Jakobsen A
Br J Cancer; 2015 Feb; 112(4):624-9. PubMed ID: 25584492
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
Gerger A; El-Khoueiry A; Zhang W; Yang D; Singh H; Bohanes P; Ning Y; Winder T; Labonte MJ; Wilson PM; Benhaim L; Paez D; El-Khoueiry R; Absenger G; Lenz HJ
Clin Cancer Res; 2011 Sep; 17(17):5783-92. PubMed ID: 21791631
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer.
Li YH; Luo HY; Wang FH; Wang ZQ; Qiu MZ; Shi YX; Xiang XJ; Chen XQ; He YJ; Xu RH
J Cancer Res Clin Oncol; 2010 Apr; 136(4):503-10. PubMed ID: 19777259
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer.
Yaman E; Uner A; Er O; Coskun U; Buyukberber S; Dikilitas M; Polat M; Yamac D; Kaya AO; Yildiz R; Ozturk B; Benekli M
Med Oncol; 2007; 24(4):431-5. PubMed ID: 17917094
[TBL] [Abstract][Full Text] [Related]
8. High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer.
Rasmussen MH; Jensen NF; Tarpgaard LS; Qvortrup C; Rømer MU; Stenvang J; Hansen TP; Christensen LL; Lindebjerg J; Hansen F; Jensen BV; Hansen TF; Pfeiffer P; Brünner N; Ørntoft TF; Andersen CL
Mol Oncol; 2013 Jun; 7(3):637-46. PubMed ID: 23506979
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Microvessel Density Using Nestin and CD34 in Colorectal Cancer.
Chabowski M; Nowak A; Grzegrzolka J; Piotrowska A; Janczak D; Dziegiel P
Anticancer Res; 2018 Jul; 38(7):3889-3895. PubMed ID: 29970509
[TBL] [Abstract][Full Text] [Related]
10. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.
Díaz-Rubio E; Gómez-España A; Massutí B; Sastre J; Abad A; Valladares M; Rivera F; Safont MJ; Martínez de Prado P; Gallén M; González E; Marcuello E; Benavides M; Fernández-Martos C; Losa F; Escudero P; Arrivi A; Cervantes A; Dueñas R; López-Ladrón A; Lacasta A; Llanos M; Tabernero JM; Antón A; Aranda E;
Oncologist; 2012; 17(1):15-25. PubMed ID: 22234633
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of intratumoral microvascular density in patients with advanced non-small cell lung cancer receiving chemotherapy plus bevacizumab.
Zhao YY; Xue C; Jiang W; Zhao HY; Huang Y; Feenstra K; Resau JH; Qian CN; Zhang L
J Thorac Oncol; 2012 Jan; 7(1):71-5. PubMed ID: 22011670
[TBL] [Abstract][Full Text] [Related]
12. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.
Boisen MK; Johansen JS; Dehlendorff C; Larsen JS; Østerlind K; Hansen J; Nielsen SE; Pfeiffer P; Tarpgaard LS; Holländer NH; Keldsen N; Hansen TF; Jensen BB; Jensen BV
Ann Oncol; 2013 Oct; 24(10):2554-2559. PubMed ID: 23864097
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
Ducreux M; Bennouna J; Hebbar M; Ychou M; Lledo G; Conroy T; Adenis A; Faroux R; Rebischung C; Bergougnoux L; Kockler L; Douillard JY;
Int J Cancer; 2011 Feb; 128(3):682-90. PubMed ID: 20473862
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.
Antonuzzo L; Giommoni E; Pastorelli D; Latiano T; Pavese I; Azzarello D; Aieta M; Pastina I; Di Fabio F; Bertolini A; Corsi DC; Mogavero S; Angelini V; Pazzagli M; Di Costanzo F
World J Gastroenterol; 2015 Jun; 21(23):7281-8. PubMed ID: 26109816
[TBL] [Abstract][Full Text] [Related]
15. Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study.
Díaz-Rubio E; Gómez-España A; Massutí B; Sastre J; Reboredo M; Manzano JL; Rivera F; Safont MJ; Montagut C; González E; Benavides M; Marcuello E; Cervantes A; Martínez de Prado P; Fernández-Martos C; Arrivi A; Bando I; Aranda E;
PLoS One; 2012; 7(10):e47345. PubMed ID: 23174912
[TBL] [Abstract][Full Text] [Related]
16. Capecitabine-based chemotherapy for metastatic colorectal cancer.
Ling W; Fan J; Ma Y; Ma Y; Wang H
J Cancer Res Clin Oncol; 2011 Jun; 137(6):927-38. PubMed ID: 20936301
[TBL] [Abstract][Full Text] [Related]
17. Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study.
Pilancı KN; Saglam S; Okyar A; Yucel S; Pala-Kara Z; Ordu C; Namal E; Ciftci R; Iner-Koksal U; Kaytan-Saglam E
Cancer Chemother Pharmacol; 2016 Jul; 78(1):143-50. PubMed ID: 27270460
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor-like domain 7 predicts response to first-line chemotherapy and bevacizumab in patients with metastatic colorectal cancer.
Hansen TF; Nielsen BS; Sørensen FB; Johnsson A; Jakobsen A
Mol Cancer Ther; 2014 Sep; 13(9):2238-45. PubMed ID: 25140000
[TBL] [Abstract][Full Text] [Related]
19. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results.
Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Rittweger K; Gilberg F; Saltz L
Br J Cancer; 2011 Jun; 105(1):58-64. PubMed ID: 21673685
[TBL] [Abstract][Full Text] [Related]
20. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]